Central Iowa Hospital Corporation

Central Iowa Hospital Corporation was paid $26.73M by Medicaid between Jan 2018 and Dec 2024, across 222 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 12% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Iowa

Rank by total paid#1 of 35

Median peer was paid$42K

This provider vs. median641×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	183,450	$2.82M
2019	188,928	$3.23M
2020	171,175	$3.48M
2021	258,452	$5.43M
2022	258,142	$5.52M
2023	234,944	$3.56M
2024incomplete	205,885	$2.69M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	12%	42,062	39,575	$3.33M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	5.4%	44,468	41,443	$1.43M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	5.2%	44,418	41,410	$1.40M
0202U	Oncology (prostate), multianalyte, gene expression profiling	4.8%	3,411	3,214	$1.28M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	4.8%	10,944	10,685	$1.27M
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	3.5%	41,500	40,046	$948K
87507		3.5%	2,605	2,451	$946K
80050	General health panel	3.4%	19,662	18,766	$897K
84443	Thyroid stimulating hormone (TSH)	2.6%	52,332	48,886	$706K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	2.4%	22,053	21,075	$648K
80061	Lipid panel	2.4%	57,033	53,457	$638K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.2%	25,610	23,992	$586K

210 more codes

80053	Comprehensive metabolic panel	2.1%	65,791	$571K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	1.7%	3,521	$454K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.6%	8,271	$424K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.6%	66,476	$422K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.5%	20,522	$404K
87660		1.4%	20,936	$379K
87480		1.4%	21,001	$379K
87510		1.4%	20,915	$378K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.4%	17,218	$369K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.3%	1,702	$360K
87086	Culture, bacterial; quantitative colony count, urine	1.3%	51,740	$353K
86481		1.2%	3,888	$325K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.2%	3,828	$310K
80048	Basic metabolic panel (calcium, ionized)	1.1%	43,781	$300K
36415	Collection of venous blood by venipuncture	1.1%	76,759	$290K
87653		1.0%	9,283	$270K
87081		<1%	42,801	$258K
86003		<1%	3,314	$224K
84439		<1%	29,856	$224K
86803		<1%	16,950	$203K
86235		<1%	1,858	$203K
86780		<1%	17,265	$198K
83036	Hemoglobin; glycosylated (A1C)	<1%	25,656	$193K
80074		<1%	4,616	$181K
87077		<1%	23,624	$180K
83655		<1%	14,848	$176K
87631		<1%	3,096	$160K
82728		<1%	12,796	$144K
85027		<1%	26,427	$142K
83970		<1%	4,064	$139K
80055		<1%	3,203	$135K
87186		<1%	17,167	$133K
82607		<1%	9,915	$122K
84702		<1%	8,637	$107K
87340		<1%	11,484	$98K
83550		<1%	13,026	$93K
83516		<1%	5,811	$89K
82784		<1%	8,395	$86K
87529		<1%	2,574	$83K
87070		<1%	10,344	$78K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,817	$78K
84403		<1%	3,542	$76K
86762		<1%	6,887	$76K
83540		<1%	13,636	$73K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,994	$73K
82570		<1%	17,664	$73K
86850		<1%	9,745	$73K
82785		<1%	5,032	$71K
83880		<1%	2,501	$68K
84146		<1%	3,915	$67K
87522	Neg quan hep c or qual rna	<1%	1,783	$66K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	4,572	$61K
87486		<1%	1,700	$60K
87581		<1%	1,702	$60K
86038		<1%	5,673	$57K
82043		<1%	12,087	$56K
84153		<1%	3,514	$54K
86140		<1%	11,780	$52K
82670		<1%	2,198	$52K
86364		<1%	4,886	$52K
83001		<1%	3,086	$49K
82951		<1%	4,268	$47K
87536		<1%	637	$45K
83690		<1%	6,978	$42K
82746		<1%	3,442	$41K
80076		<1%	5,702	$39K
86706		<1%	4,259	$38K
86376		<1%	2,942	$37K
87505		<1%	329	$37K
84481		<1%	2,533	$37K
86800		<1%	2,650	$37K
87205		<1%	9,538	$37K
84480		<1%	2,852	$36K
83735		<1%	7,105	$36K
86480		<1%	640	$36K
84460		<1%	8,282	$35K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	424	$34K
80069		<1%	5,420	$32K
86665		<1%	1,066	$31K
82950		<1%	7,517	$30K
86787		<1%	2,587	$30K
83525		<1%	2,925	$28K
81001		<1%	11,321	$28K
84144		<1%	1,681	$28K
85652		<1%	11,631	$27K
83002		<1%	1,780	$27K
82105		<1%	2,145	$27K
85610		<1%	7,783	$25K
86360		<1%	568	$22K
86900		<1%	8,718	$21K
86901		<1%	8,528	$20K
85018		<1%	9,621	$20K
80197		<1%	2,050	$19K
86696		<1%	1,129	$19K
84450		<1%	4,528	$19K
82274		<1%	1,373	$19K
84156		<1%	6,537	$19K
80164		<1%	1,710	$18K
83520		<1%	1,330	$17K
87400		<1%	681	$17K
86431		<1%	3,324	$17K
82150		<1%	2,690	$15K
82627		<1%	805	$15K
82550		<1%	2,629	$14K
86618		<1%	490	$13K
82977		<1%	2,253	$13K
82533		<1%	978	$13K
82565		<1%	3,258	$13K
86695		<1%	1,130	$13K
84550		<1%	3,240	$12K
84681		<1%	690	$12K
80177		<1%	1,004	$12K
82248		<1%	2,694	$12K
81025		<1%	1,622	$12K
86039		<1%	1,201	$11K
84703		<1%	1,619	$11K
85379		<1%	1,274	$11K
87147		<1%	2,352	$11K
84165		<1%	1,218	$11K
86704		<1%	1,138	$10K
86200		<1%	913	$10K
82947		<1%	2,891	$10K
86705		<1%	972	$10K
81003		<1%	4,851	$9K
87102		<1%	1,239	$9K
87206		<1%	1,184	$9K
82247		<1%	1,741	$8K
86708		<1%	758	$8K
85730		<1%	1,641	$8K
86255		<1%	582	$8K
84100		<1%	1,817	$7K
82390		<1%	722	$7K
87116		<1%	638	$6K
83721		<1%	1,001	$6K
84484		<1%	610	$6K
86258		<1%	341	$6K
83615		<1%	1,079	$6K
87338		<1%	463	$6K
84134		<1%	515	$6K
88142		<1%	266	$5K
86645		<1%	355	$5K
86334		<1%	282	$5K
86769		<1%	107	$5K
88141		<1%	215	$5K
86644		<1%	365	$4K
80320		<1%	435	$4K
88112		<1%	303	$4K
85014		<1%	1,955	$4K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	794	$4K
87015		<1%	644	$4K
82103		<1%	358	$4K
84446		<1%	332	$4K
86381		<1%	165	$4K
82952		<1%	928	$3K
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	457	$3K
87075		<1%	379	$3K
86592		<1%	817	$3K
84132		<1%	878	$3K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	20	$3K
82040		<1%	701	$2K
36416		<1%	3,353	$2K
86215		<1%	160	$2K
85046		<1%	412	$2K
80178		<1%	344	$2K
87106		<1%	184	$2K
86060		<1%	241	$2K
82465		<1%	579	$2K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	54	$2K
86160		<1%	108	$1K
84520		<1%	454	$1K
84436		<1%	289	$1K
87634		<1%	28	$1K
84478		<1%	300	$977.34
82310		<1%	239	$886.61
87324		<1%	218	$840.46
83883		<1%	54	$827.08
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	2,312	$775.20
87493		<1%	27	$766.59
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	50	$757.86
84155		<1%	271	$752.82
82610		<1%	126	$677.23
81015		<1%	254	$673.87
86308		<1%	146	$603.32
85048		<1%	375	$578.86
86735		<1%	37	$550.80
87181		<1%	16	$540.06
87799		<1%	25	$505.72
87807		<1%	42	$473.10
86664		<1%	26	$397.64
87040		<1%	28	$313.60
86015		<1%	29	$276.33
87184		<1%	32	$226.95
87185		<1%	57	$223.84
84305		<1%	16	$189.25
0352U		<1%	7,222	$182.88
86225		<1%	12	$149.18
86870		<1%	16	$130.00
80156		<1%	17	$123.06
83718		<1%	16	$116.70
84590		<1%	13	$91.46
0064U		<1%	4,017	$86.50
83010		<1%	18	$81.95
85660		<1%	13	$52.95
83521		<1%	113	$17.61
3051F		0%	284	$0.00
0097U		0%	590	$0.00
3046F		0%	230	$0.00
3052F		0%	205	$0.00
3044F		0%	2,558	$0.00
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	0%	62	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSTARK, DAVID (CEO)